Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in Thailand

Phase 1

Completed

• Conditions: HIV Infections
• Interventions: Drug: GPO-Vir Z30 tablet; Drug: Lamivudine; Drug: Nevirapine; Drug: Zidovudine

• Registration Number: NCT00672412
• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary

In 2005, there were 50,620 HIV-infected children living in Thailand. Current anti-HIV regimens, comprised of individual pills for each drug, frequently lead to missed doses. To properly control their infection, regimens that are tolerable and effective in children and without pill burden are necessary. The primary purpose of this study is to evaluate the safety and bioavailability of GPO-VIR Z30, a combination fixed dose tablet containing zidovudine (ZDV), lamivudine (3TC), and nevirapine (NVP), in HIV-infected children in Thailand.

Detailed Description

An important factor affecting the therapeutic response to ARVs is adherence. A common reason for poor adherence is high pill burden. A combination fixed dose drug approach appears to be an effective strategy to improve adherence and therapeutic response. In this study, investigators will compare the bioavailability and safety of GPO-VIR Z30, a combination fixed dose drug, with the liquid formulations of ZDV,3TC, and NVP, in children.

This study will last approximately 8 weeks. Participants will be randomly assigned to one of two arms. Participants in Arm 1 will receive GPO-VIR Z30 for 2 weeks before receiving liquid formulations of ZDV, 3TC, and NVP for the following 2 weeks. Participants in Arm 2 will receive liquid formulations of ZDV, 3TC, and NVP for 2 weeks before receiving GPO-VIR Z30 for the following 2 weeks.

This study will consist of 4 study visits after screening. Visits will occur at study entry and on Days 14, 28, and 56. Medical history and a physical exam will occur at all visits. A pregnancy test will occur for females at all visits. Pharmacokinetic tests, involving hospitalization for the 12 hour procedure, will occur on Days 14 and 28. Safety and adherence monitoring will occur by telephone on Days 7, 11 or 12, 13, 21, 25 or 26, 27, and 35. Home visits for directly observed therapy (DOT) may also occur.

Study Timeline

• Study First Submitted: 2008-05-02
• Study First Submitted QC: 2008-05-02
• Study First Posted: 2008-05-06
• Study Start: 2008-10
• Primary Completion: 2010-01
• Study Completion: 2010-01
• Disposition First Submitted: 2010-12-20
• Disposition First Submitted QC: 2011-04-15
• Disposition First Posted: 2011-04-27
• Status Verified: 2012-09
• Last Update Submitted: 2021-11-03
• Last Update Posted: 2021-11-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

• Weigh between 6 and 30 kilograms
• HIV infected
• Receiving HAART regimen of NVP and 2 NRTIs. More information on this criterion can be found in the protocol.
• Agree to use two appropriate forms of contraception. More information on this criterion can be found in the protocol.
• Ability to swallow study drugs
• Willing to be hospitalized for 12-hour intensive PK study
• Agree to use two appropriate forms of contraception. More information on this criterion can be found in the protocol.
• Parent or legal guardian able and willing to provide written informed consent

Exclusion Criteria

• Certain abnormal laboratory values. More information on this criterion can be found in the protocol.
• Vomiting or diarrhea (greater than Grade 2) within 30 days prior to study entry
• History of immunologic failure. More information on this criterion can be found in the protocol.
• Current treatment for an acute serious bacterial, viral, or opportunistic infection
• History of dose-limiting toxicity requiring treatment discontinuation of any of the study drugs
• Hypersensitivity to study drugs
• Surgical or medical problem affecting gastrointestinal motility or absorption or liver function
• Treatment with experimental drugs within 30 days prior to study entry
• Acute hepatitis
• Chemotherapy for active malignancy
• Any clinically significant diseases or findings during the screening medical history or physical examination that, in the opinion of the investigator, may interfere with the study
• Pregnant

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
1	GPO-Vir Z30 tablet	Participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive liquid ZDV, 3TC, and NVP for the following 14 days of the study.
1	Lamivudine	Participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive liquid ZDV, 3TC, and NVP for the following 14 days of the study.
2	GPO-Vir Z30 tablet	Participants receive liquid ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the following 14 days of the study.
1	Nevirapine	Participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive liquid ZDV, 3TC, and NVP for the following 14 days of the study.
2	Nevirapine	Participants receive liquid ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the following 14 days of the study.
1	Zidovudine	Participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive liquid ZDV, 3TC, and NVP for the following 14 days of the study.
2	Lamivudine	Participants receive liquid ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the following 14 days of the study.
2	Zidovudine	Participants receive liquid ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the following 14 days of the study.

Primary Outcome Measures

Name	Time	Method
Safety and comparative bioavailability measured by concentration difference between the GPO-Vir Z30 and standard liquid regimens	Throughout study
Therapeutic adequacy of NVP measured by treatment-specific concentration distributions	Throughout study

Secondary Outcome Measures

Name	Time	Method
Comparisons in PK analyses between GPO-VIR Z30 and standard liquid regimens including pharmacokinetic parameters, adverse drug reactions, and the influence of SNPs on NVP pharmacokinetic parameters	Throughout study

Trial Locations

Locations (4)

Prapokklao Hosp. CRS; 🇹🇭 Muang District, Chantaburi, Thailand

Siriraj Hospital Mahidol University CRS; 🇹🇭 Bangkok, Ratchathewi, Thailand

Chonburi Hosp. CRS; 🇹🇭 Chonburi, Thailand

Chiang Mai University Pediatrics-Obstetrics CRS; 🇹🇭 Chiang Mai, Thailand